2. Academic Validation
  3. Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment

  • Eur J Pharmacol. 2023 Aug 5:952:175752. doi: 10.1016/j.ejphar.2023.175752.
Aoli Wang 1,  Juan Liu 1,  Xixiang Li 1,  Fengming Zou 1,  Ziping Qi 1,  Shuang Qi 1,  Qingwang Liu 1,  Zuowei Wang 1,  Jiangyan Cao 1,  Zongru Jiang 2,  Beilei Wang 1,  Juan Ge 3,  Li Wang 1,  Wenchao Wang 4,  Jing Liu 5,  Qingsong Liu 6
Affiliations

Affiliations

  • 1 Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China; Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China.
  • 2 Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China.
  • 3 Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China; University of Science and Technology of China, Hefei, Anhui, 230026, PR China.
  • 4 Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China; Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China; University of Science and Technology of China, Hefei, Anhui, 230026, PR China. Electronic address: wwcbox@hmfl.ac.cn.
  • 5 Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China; Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China; University of Science and Technology of China, Hefei, Anhui, 230026, PR China. Electronic address: jingliu@hmfl.ac.cn.
  • 6 Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China; Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China; University of Science and Technology of China, Hefei, Anhui, 230026, PR China; Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui, 230088, PR China. Electronic address: qsliu97@hmfl.ac.cn.
PMID: 37164118 DOI: 10.1016/j.ejphar.2023.175752
Abstract

Although rat sarcoma viral oncogene homolog (Ras) mutations occur in about 30% of solid tumors, targeting Ras mutations other than KRAS-G12C is still challenging. As an alternative approach, developing inhibitors targeting Raf, the downstream effector of Ras signaling, is currently one of the main strategies for Cancer therapy. Selective v-raf murine sarcoma viral oncogene homolog B1 (BRaf)-V600E inhibitors Vemurafenib, Encorafenib, and Dabrafenib have been approved by FDA and received remarkable clinical responses, but these drugs are ineffective against Ras mutant tumors due to limited inhibition on dimerized Raf. In this study, we developed a highly potent pan-RAF inhibitor, IHMT-RAF-128, which exhibited similarly high efficacies in inhibiting both partners of the Raf dimer, and showed potent anti-tumor efficacy against a variety of Cancer cells harboring either Raf or Ras mutations, especially Adagrasib and Sotorasib (AMG510) resistant-KRAS-G12C secondary mutations, such as KRAS-G12C-Y96C and KRAS-G12C-H95Q. In addition, IHMT-RAF-128 showed excellent pharmacokinetic profile (PK), and the bioavailability in mice and rats were 63.9%, and 144.1%, respectively. Furthermore, IHMT-RAF-128 exhibited potent anti-tumor efficacy on xenograft mouse tumor models in a dose-dependent manner without any obvious toxicities. Together, these results support further investigation of IHMT-RAF-128 as a potential clinical drug candidate for the treatment of Cancer patients with Raf or Ras mutations.

Keywords

BRAF; Cancer therapy; Pan-RAF; RAS mutations; Vemurafenib.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z